Teva Q2 revenue $3.8B, non-GAAP EPS $0.68; reaches $4.25B opioids settlement in principle

TEVA PHARMACEUTICAL INDUSTRIES LTD

2022-Q2 EPS reported -$1.07 revenue$7,447,000,000

Revenue $3.8B (-3% YoY, +1% local currency); GAAP loss $0.21, non-GAAP EPS $0.68 vs $0.59 prior year
Agreed in principle to nationwide opioids settlement: up to $4.25B + $100M for tribes over 13 years, includes Narcan supply
Revised 2022 revenue guidance to $15.0-$15.6B from $15.4-$16.0B due to FX; reaffirmed adjusted EBITDA, EPS, FCF
COPAXONE outlook lowered to ~$700M from ~$750M; non-GAAP tax rate outlook cut to 13%-14% from 18%-19%
Cash flow from ops $123M, free cash flow $301M; goodwill impairment and legal settlements drove GAAP loss

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.